|
000
| 01905nam 2200421zi 4500 |
|---|
| 001 | 9.933796 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240725133201 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 240212e202403 onca ob f000 0 eng d |
|---|
| 020 | |a9780660702100 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-327/2024E-PDF |
|---|
| 245 | 00|aGuidance on nitrosamine impurities in medications. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cMarch 2024. |
|---|
| 264 | 4|c©2024 |
|---|
| 300 | |a1 online resource (iii, 56 pages) : |billustrations |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. |
|---|
| 500 | |a"Date Adopted: 2024-03-15. Effective Date: 2024-03-15." |
|---|
| 500 | |a"Pub.: 230750." |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover. |
|---|
| 650 | 0|aNitrosoamines|xRisk assessment|zCanada. |
|---|
| 650 | 0|aDrugs|xRisk assessment|zCanada. |
|---|
| 650 | 0|aBiologicals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aRadiopharmaceuticals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrices sur les impuretés de nitrosamine dans les médicaments.|w(CaOODSP)9.933797 |
|---|
| 794 | |tGuidance on nitrosamine impurities in medications.|b(May 2024)|w(CaOODSP)9.938524 |
|---|
| 795 | |tGuidance on nitrosamine impurities in medications.|b(October 2023)|w9.928221 |
|---|
| 856 | 40|qPDF|s1.13 MB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H164-327-2024-eng.pdf |
|---|